세계의 혈소판 응집 기기 시장 보고서 : 제품 유형, 용도, 최종 사용자 및 지역별(2024-2032년)

The global platelet aggregation devices market size reached US$ 556.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 893.3 Million by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.

Platelet aggregation devices comprise adenosine-diphosphate (ADP), thrombin, and ristocetin-induced platelet aggregation (RIPA). These devices are used to diagnose patients with inherited and acquired platelet function disorders, such as excessive bleeding, arterial thrombotic, stroke, and myocardial infarction. They assist in transfusing medicines, pre-surgery tests, and clinical settings to monitor the response of antiplatelet therapies and assess perioperative bleeding risk. At present, due to the launch of new potential biomarkers and technologies, platelet aggregation devices are finding extensive application in personalizing antiplatelet drugs and monitoring the efficacy of various types of pro-hemostatic therapies around the world.

Platelet Aggregation Devices Market Trends:

The rising instances of platelet aggregation among patients diagnosed with coronavirus disease (COVID-19) are strengthening the growth of the market. Moreover, due to the growing prevalence of colon cancer, cardiovascular diseases, Kawasaki condition, acute coronary syndrome (ACS), acute ischemic stroke, and acute rheumatic disorders across the globe, there is an increase in the risk of bleeding. This acts as another key factor impelling the growth of the platelet aggregation devices market for clinical management of platelet function disorders. In addition, a significant rise in the aging population suffering from chronic diseases is contributing to the market growth. Apart from this, leading manufacturers are launching novel products to expand their product portfolio and retain a competitive edge in the market. They are also focusing on developing new and simpler point-of-care (POC) diagnostic devices. These devices rely on the latest methodologies for helping in the rapid evaluation of inherited and acquired bleeding disorders and antiplatelet therapies. This, coupled with the increasing need for POC diagnostic devices to fulfill the healthcare demand of the large population, is projected to drive the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global platelet aggregation devices market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, type, application and end user.

Breakup by Product:

• Systems
• Reagents
• Consumables and Accessories

Breakup by Type:

• Four Channel
• Dual Channel
• Eight Channel

Breakup by Application:

• Clinical Applications
• Research Applications
• Cardiovascular Applications
• Orthopedic Applications
• Others

Breakup by End User:

• Hospitals
• Diagnostic Laboratories
• Research and Academic Institutes
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aggredyne Inc., Chrono-Log Corporation, F. Hoffmann-La Roche AG, Grifols S.A., Hart Biologicals Ltd., Helena Laboratories Corporation, LAbor BioMedical Technologies GmbH, Matis Medical Inc., Sentinel Ch. S.P.A., Siemens AG, Sienco Inc., Sysmex Corporation and WerfenLife SA.

Key Questions Answered in This Report

• 1. What was the size of the global platelet aggregation devices market in 2023?
• 2. What is the expected growth rate of the global platelet aggregation devices market during 2024-2032?
• 3. What has been the impact of COVID-19 on the global platelet aggregation devices market?
• 4. What are the key factors driving the global platelet aggregation devices market?
• 5. What is the breakup of the global platelet aggregation devices market based on the product?
• 6. What is the breakup of the global platelet aggregation devices market based on the type?
• 7. What is the breakup of the global platelet aggregation devices market based on the application?
• 8. What is the breakup of the global platelet aggregation devices market based on the end user?
• 9. What are the key regions in the global platelet aggregation devices market?
• 10. Who are the key players/companies in the global platelet aggregation devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Platelet Aggregation Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Systems
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Reagents
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Consumables and Accessories
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Type

• 7.1 Four Channel
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Dual Channel
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Eight Channel
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Clinical Applications
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Research Applications
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Cardiovascular Applications
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Orthopedic Applications
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Diagnostic Laboratories
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Research and Academic Institutes
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Aggredyne Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Chrono-Log Corporation
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 F. Hoffmann-La Roche AG
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 SWOT Analysis
  • 15.3.4 Grifols S.A.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Hart Biologicals Ltd.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Helena Laboratories Corporation
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 LAbor BioMedical Technologies GmbH
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Matis Medical Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 Sentinel Ch. S.P.A.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Siemens AG
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Sienco Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
  • 15.3.12 Sysmex Corporation
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 WerfenLife SA
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio